Clinical trial
Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid…
NCT00364143 · Yakult Honsha Co., LTD, Industry · Completed
Key facts
| NCT number | NCT00364143 |
|---|---|
| Title | Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors |
| Official title | A Phase I Study of IHL-305 (Irinotecan Liposome Injection) in Patients With Advanced Solid Tumors |
| Lead sponsor | Yakult Honsha Co., LTD, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | IHL-305 (irinotecan liposome injection) |
| Enrollment | 40 |
| Start date | Sep 1, 2006 |
| Completion | Jun 1, 2011 |
| First posted | Aug 15, 2006 |
| Last update posted | Jul 5, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: